What is WAVE Life Sciences Price-to-Free-Cash-Flow?
As of today (2024-12-15), WAVE Life Sciences's share price is €13.00.
WAVE Life Sciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.04. Hence, WAVE Life Sciences's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for WAVE Life Sciences's Price-to-Free-Cash-Flow or its related term are showing as below:
STU:1U5's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.18 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 59.80% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 31.20% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was -10.10% per year.
During the past 11 years, WAVE Life Sciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 59.80% per year. The lowest was -152.60% per year. And the median was -4.45% per year.
WAVE Life Sciences Price-to-Free-Cash-Flow Historical Data
The historical data trend for WAVE Life Sciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WAVE Life Sciences's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, WAVE Life Sciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Price-to-Free-Cash-Flow falls into.
WAVE Life Sciences Price-to-Free-Cash-Flow Calculation
WAVE Life Sciences's Price-to-Free-Cash-Flow ratio for today is calculated as
WAVE Life Sciences's Share Price of today is €13.00. WAVE Life Sciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
WAVE Life Sciences (STU:1U5) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
WAVE Life Sciences Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of WAVE Life Sciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:1U5 has been successfully added to your 